Key Details
The National Pharmaceutical Pricing Authority’s (NPPA) October 2026 order extends trade-margin controls to cancer medicines that are not covered by the usual ceiling prices for essential medicines.
Coverage: 137 non-scheduled anti-cancer medicines, including patented drugs, across their strengths, forms and combinations.
Price rule: The margin between the March 2026 distributor price and the maximum retail price (MRP) cannot exceed 30% of the MRP, excluding GST.
Prices reported: By 4 November, 70 companies had submitted revised MRPs for 120 medicines, covering 1,136 individual products. Reported reductions range from 20% to 70% on average, with the largest at 96.45%.
Start date: The revised prices take effect on 9 November 2026. A medicine already priced below the new limit cannot be made more expensive.
Savings estimate: ₹3,357.49 crore is the difference between old and revised prices applied to April 2025–March 2026 sales volumes. It is a projection based on past sales, not savings already received by patients.
The Cap Targets the Mark-Up Between Distributor and Patient Prices
A trade margin is the difference between a medicine’s price to a stockist or distributor and its MRP. The order responds to concerns about large gaps between procurement prices and what patients could be charged at retail and hospital pharmacies. It limits that margin for the listed medicines rather than setting one common price for every cancer drug.
Most non-scheduled medicines are ordinarily monitored through a limit on annual MRP increases. The NPPA has instead used its extraordinary public-interest power under the Drugs (Prices Control) Order, 2013 to intervene directly in these medicines’ prices. This expands on a 2019 trade-margin intervention covering 42 non-scheduled anti-cancer drugs.
Patients Need to See the Revised Price Where They Buy Treatment
Manufacturers must report and publicise their new MRPs and communicate them to retailers and hospitals. Patients can check listed prices through the NPPA website or Pharma Sahi Daam app. The order also restricts manufacturers from reducing production without permission and requires notice before discontinuing a medicine—safeguards intended to protect availability as prices fall.
The cap addresses medicine prices, not the full cost of cancer care. Insurance coverage, diagnosis and treatment facilities remain relevant to whether patients can obtain the prescribed drugs.
Policy Relevance
The immediate question is whether the notified reductions reach hospital and retail bills from 9 November, including for patients buying patented medicines. Comparing actual selling prices with revised MRPs, while tracking availability, would show whether the cap lowers out-of-pocket spending without disrupting supply. The remaining price submissions also matter: as of 4 November, companies had reported revisions for 120 of the 137 medicines.
Relevant Question for Policy Stakeholders: How will the NPPA verify that pharmacies and hospitals charge the revised prices while maintaining supplies of the affected cancer medicines?
Follow the Full News Here: Cheaper Cancer Medicines: What the New Margin Cap Means for Patients